RxDoctor Payments Data

Fred Chiu, MD

Pain Medicine · Terrytown, LANPI 1558557272

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,838 of the $3,770 with a category attached, or 75.3%. 41 manufacturers reported payments, led by Stryker at 26.7% of the total. That places this record below the midpoint for pain medicine clinicians in LA, where the typical reported total is $3,650.

$3,770in general payments, 2019–2025

Across 139 payments — averaging $27.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$1K
  • Collegium Pharmaceutical, Inc.$326
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$298
  • Forte Bio-pharma LLC$275
  • Boston Scientific$170
  • Globus Medical$149
  • plus $2K from 35 others

What the payments were for

  • Speaking & faculty fees$321%
  • Travel & lodging$90024%
  • Food & beverage$2,83875%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,770 in reported general payments places this provider in the 50th percentile of 97 pain medicine providers in Louisiana.

See all pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$129,520
Medicare patients
154
Services billed
1,718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen2,673$148,824
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,946$67,935
MovantikNaloxegol Oxalate57$23,216
Xtampza ErOxycodone Myristate28$17,862
Gabapentin1,176$15,907
Tizanidine Hcl1,609$12,700
Morphine Sulfate ErMorphine Sulfate184$8,090
Lidocaine68$8,065
Buprenorphine27$6,569
Tramadol Hcl636$6,399
Pregabalin371$5,718
Oxycodone Hcl324$4,342
Fentanyl47$3,733
Methocarbamol248$3,378
Zonisamide114$2,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Redhill Biopharma Inc.Movantik$18$23,21657 claims
Collegium Pharmaceutical, Inc.Xtampza Er$326$17,86228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 97 pain medicine providers in Louisiana.

Other pain medicine in Terrytown

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →